Should I buy or sell Treace Medical Concepts stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TMCI shares. View TMCI analyst ratings or view top-rated stocks .

What is Treace Medical Concepts' stock price target for 2024?

6 analysts have issued 12 month price targets for Treace Medical Concepts' stock. Their TMCI share price targets range from $11.00 to $27.50. On average, they predict the company's stock price to reach $18.92 in the next twelve months. This suggests a possible upside of 111.4% from the stock's current price. View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts .

How have TMCI shares performed in 2023?

Treace Medical Concepts' stock was trading at $22.99 at the beginning of 2023. Since then, TMCI shares have decreased by 61.1% and is now trading at $8.95. View the best growth stocks for 2023 here .

When is Treace Medical Concepts' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our TMCI earnings forecast .

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) issued its quarterly earnings results on Thursday, November, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.02. The business earned $40.76 million during the quarter, compared to analyst estimates of $42.08 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 37.68% and a negative net margin of 27.28%.

When did Treace Medical Concepts IPO?

(TMCI) raised $150 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Who are Treace Medical Concepts' major shareholders?

Treace Medical Concepts' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include William Blair Investment Management LLC (2.90%), Emerald Advisers LLC (2.39%), TimesSquare Capital Management LLC (2.32%), Emerald Mutual Fund Advisers Trust (1.94%), Loomis Sayles & Co. L P (1.83%) and Kornitzer Capital Management Inc. KS (1.10%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace , John R Treace , John T Treace , Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan , Terry W Lubben and Thomas E Timbie . View institutional ownership trends .

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Treace Medical Concepts Stock Price, News & Analysis (NASDAQ:TMCI)

$9.08

+0.13 (+1.45%)

(As of 10:03 AM ET)

Compare

Today's Range: $8.89
▼
$9.12
50-Day Range: $6.03
▼
$13.11
52-Week Range: $5.27
▼
$27.97

Volume: 26,313 shs
Average Volume: 562,025 shs
Market Capitalization: $560.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.92

Treace Medical Concepts MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 111.4% Upside
$18.92 Price Target
Short Interest: Bearish
8.63% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.79) to ($0.58) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

192nd out of 949 stocks

Surgical & Medical Instruments Industry

26th out of 82 stocks

4.4

Analyst's Opinion

Consensus Rating
Treace Medical Concepts has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.92, Treace Medical Concepts has a forecasted upside of 111.4% from its current price of $8.95.
Amount of Analyst Coverage
Treace Medical Concepts has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
8.63% of the float of Treace Medical Concepts has been sold short.
Short Interest Ratio / Days to Cover
Treace Medical Concepts has a short interest ratio ("days to cover") of 4.3.
Change versus previous month
Short interest in Treace Medical Concepts has recently decreased by 2.58%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Treace Medical Concepts does not currently pay a dividend.
Dividend Growth
Treace Medical Concepts does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TMCI.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Treace Medical Concepts this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for TMCI on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Treace Medical Concepts to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Treace Medical Concepts insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.69% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.85% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Treace Medical Concepts are expected to grow in the coming year, from ($0.79) to ($0.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Treace Medical Concepts is -11.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Treace Medical Concepts is -11.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Treace Medical Concepts has a P/B Ratio of 8.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Treace Medical Concepts Stock (NASDAQ:TMCI)

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision; and Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

TMCI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TMCI Stock News Headlines

December 3, 2023 | americanbankingnews.com

Analyzing DarioHealth (NASDAQ:DRIO) & Treace Medical Concepts (NASDAQ:TMCI)

December 1, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Treace Medical Concepts (TMCI), Arvinas Holding Company (ARVN) and Cooper Co (COO)

December 6, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 27, 2023 | markets.businessinsider.com

Ryan Zimmerman Reaffirms Buy Rating on Treace Medical Concepts Amid Anticipated FY24 Rebound and Strategic Growth Initiatives

November 26, 2023 | americanbankingnews.com

Treace Medical Concepts (NASDAQ:TMCI) Sees Large Volume Increase

November 24, 2023 | morningstar.com

Treace Medical Concepts Inc TMCI

November 12, 2023 | finance.yahoo.com

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q3 2023 Earnings Call Transcript

November 11, 2023 | benzinga.com

Treace Medical Concepts Stock (NASDAQ:TMCI), Analyst Ratings, Price Targets, Predictions

December 6, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 10, 2023 | marketwatch.com

Treace Medical Shares Hit All-Time Low After Outlook Cut

November 10, 2023 | finance.yahoo.com

Q3 2023 Treace Medical Concepts Inc Earnings Call

November 9, 2023 | markets.businessinsider.com

Treace Medical Concepts Disappoints On Q3 Results, Lowers FY23 Guidance

November 9, 2023 | finance.yahoo.com

Treace Medical Concepts Reports Third Quarter 2023 Financial Results

October 30, 2023 | finance.yahoo.com

Treace to Present at Stifel 2023 Healthcare Conference

October 28, 2023 | seekingalpha.com

TMCI Treace Medical Concepts, Inc.

October 27, 2023 | seekingalpha.com

Treace Medical Concepts Continues Growth Investments Despite High Operating Losses

October 16, 2023 | finance.yahoo.com

Treace to Report Third Quarter 2023 Financial Results

September 29, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Treace Medical Concepts

September 20, 2023 | finance.yahoo.com

Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023

September 17, 2023 | fool.com

Treace Medical Concepts (NASDAQ: TMCI)

September 14, 2023 | finance.yahoo.com

Treace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. Patent

September 11, 2023 | finance.yahoo.com

Treace Medical Concepts Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related Procedures

August 22, 2023 | finance.yahoo.com

Treace Announces Participation in the 21st Annual Morgan Stanley Global Healthcare Conference

August 21, 2023 | finance.yahoo.com

Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

August 11, 2023 | nasdaq.com

Stephens & Co. Maintains Treace Medical Concepts (TMCI) Equal-Weight Recommendation

August 10, 2023 | nasdaq.com

Truist Securities Maintains Treace Medical Concepts (TMCI) Buy Recommendation

August 9, 2023 | seekingalpha.com

Treace Medical Concepts Non-GAAP EPS of -$0.20, revenue of $42M

See More Headlines

Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/05/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TMCI
CUSIP: N/A
CIK: 1630627
Web: www.treace.com
Phone: 904-373-5940
Fax: N/A
Employees: 423
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.92
High Stock Price Target: $27.50
Low Stock Price Target: $11.00
Potential Upside/Downside: +111.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,810,000.00
Net Margins: -27.28%
Pretax Margin: -27.28%
Return on Equity: -37.68%
Return on Assets: -21.22%

Debt

Debt-to-Equity Ratio: 0.38
Current Ratio: 5.64
Quick Ratio: 4.76

Sales & Book Value

Annual Sales: $174.68 million
Price / Sales: 3.16
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.09 per share
Price / Book: 8.21

Miscellaneous

Outstanding Shares: 61,676,000
Free Float: 43,981,000
Market Cap: $552.00 million
Optionable: Not Optionable
Beta: 0.05

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. John T. Treace (Age 51)
CEO, Founder & Director
Comp: $1.04M
Mr. Mark L. Hair CPA (Age 53)
Chief Financial Officer
Comp: $628.6k
Mr. Aaron J. Berutti (Age 44)
Senior Vice President of Sales
Comp: $519.41k
Mr. Terry W. Lubben (Age 58)
Senior Vice President of Operations
Ms. Julie D. Dewey (Age 62)
Chief Communications & Investor Relations Officer
Mr. Scot M. Elder (Age 48)
Chief Legal & Compliance Officer and Corporate Secretary
Mr. Nathan Minnich
Senior Vice President of Marketing
Mr. Daniel E. Owens (Age 51)
Chief Human Resources Officer
Mr. Jaime A. Frias (Age 61)
Chief Business Development Officer
Comp: $271.04k
Dr. Sean F. Scanlan Ph.D. (Age 40)
Chief Innovation Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TMCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Treace Medical Concepts stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TMCI shares.
View TMCI analyst ratings or view top-rated stocks.
What is Treace Medical Concepts' stock price target for 2024?: 6 analysts have issued 12 month price targets for Treace Medical Concepts' stock. Their TMCI share price targets range from $11.00 to $27.50. On average, they predict the company's stock price to reach $18.92 in the next twelve months. This suggests a possible upside of 111.4% from the stock's current price.
View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts.
How have TMCI shares performed in 2023?: Treace Medical Concepts' stock was trading at $22.99 at the beginning of 2023. Since then, TMCI shares have decreased by 61.1% and is now trading at $8.95.
View the best growth stocks for 2023 here.
When is Treace Medical Concepts' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our TMCI earnings forecast.

How were Treace Medical Concepts' earnings last quarter?: Treace Medical Concepts, Inc. (NASDAQ:TMCI) issued its quarterly earnings results on Thursday, November, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.02. The business earned $40.76 million during the quarter, compared to analyst estimates of $42.08 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 37.68% and a negative net margin of 27.28%.
When did Treace Medical Concepts IPO?: (TMCI) raised $150 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.
Who are Treace Medical Concepts' major shareholders?: Treace Medical Concepts' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include William Blair Investment Management LLC (2.90%), Emerald Advisers LLC (2.39%), TimesSquare Capital Management LLC (2.32%), Emerald Mutual Fund Advisers Trust (1.94%), Loomis Sayles & Co. L P (1.83%) and Kornitzer Capital Management Inc. KS (1.10%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie.
View institutional ownership trends.
How do I buy shares of Treace Medical Concepts?: Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TMCI) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial